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Dynamic Oligomerization of 
Integrase Orchestrates HIV Nuclear 
Entry
Doortje Borrenberghs1,2,*, Lieve Dirix1,2,*, Flore De Wit1, Susana Rocha2, Jolien Blokken1, 
Stéphanie De Houwer1, Rik Gijsbers3, Frauke Christ1, Johan Hofkens2, Jelle Hendrix2,† & 
Zeger Debyser1
Nuclear entry is a selective, dynamic process granting the HIV-1 pre-integration complex (PIC) access to 
the chromatin. Classical analysis of nuclear entry of heterogeneous viral particles only yields averaged 
information. We now have employed single-virus fluorescence methods to follow the fate of single viral 
pre-integration complexes (PICs) during infection by visualizing HIV-1 integrase (IN). Nuclear entry is 
associated with a reduction in the number of IN molecules in the complexes while the interaction with 
LEDGF/p75 enhances IN oligomerization in the nucleus. Addition of LEDGINs, small molecule inhibitors 
of the IN-LEDGF/p75 interaction, during virus production, prematurely stabilizes a higher-order IN 
multimeric state, resulting in stable IN multimers resistant to a reduction in IN content and defective 
for nuclear entry. This suggests that a stringent size restriction determines nuclear pore entry. Taken 
together, this work demonstrates the power of single-virus imaging providing crucial insights in HIV 
replication and enabling mechanism-of-action studies.
Although active nuclear import is a hallmark in the replication cycle of lentiviruses such as the human immuno-
deficiency virus type 1 (HIV-1), nuclear entry is one of the least understood steps1–4. After reverse transcription of 
the viral RNA into double stranded DNA, the pre-integration complex (PIC) is formed as an assembly of the viral 
DNA (vDNA) and cellular and viral proteins. Prior to integration, the PIC has to cross the natural barrier of the 
nuclear membrane through nuclear pore complexes (NPCs) which serve as selective entry gates5. Recent evidence 
suggests that uncoating of the HIV capsid (CA) core occurs close to the nuclear membrane although some CA 
molecules may accompany the PIC into the nucleus6–9. Genome-wide siRNA screens identified the nucleoporins 
Nup153 and Nup358 (RANBP2) as host cofactors of HIV nuclear import10–13. Nup358 binds CA14 and is believed 
to act as a docking station for the HIV PIC10,14. Nup153 is located in the nuclear basket; interactions between its 
FG repeats and either viral integrase (IN) or CA are in line with a role during nuclear entry10,15,16. Besides nucleo-
porins, importin α /β , importin 7 and Transportin-SR2 (TRN-SR2, TNPO3) have been proposed to be involved 
in nuclear import of the PIC1,17–20. A role for the HIV DNA flap in nuclear import has been proposed as well21,22.
HIV-1 IN mediates the insertion of the viral cDNA in two consecutive steps: 3′ processing and strand transfer23. 
IN catalytic activity is highly dependent on a dynamic equilibrium of IN multimers; evidence indicates that 
3′ processing requires at least a dimer whereas at least a tetramer is needed for concerted integration24–28. In line 
with this, the prototype foamy virus (PFV) intasome has been shown to consist of an IN tetramer29. Concerted inte-
gration of the HIV cDNA occurs into active transcription sites30,31 and is guided by the host factor LEDGF/p7532–34. 
LEDGF/p75 contains an N-terminal chromatin/DNA binding moiety (residues 1–325) and a C-terminal inte-
grase binding domain (IBD, residues 347–429)35,36. The pivotal role of LEDGF/p75 in HIV-1 replication was 
revealed via mutagenesis, RNAi-mediated depletion, transdominant overexpression of the IBD of LEDGF/p75 
and cellular knockout studies32,33,37–43.
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Structure-based drug design gave rise to 2-(tert-butoxy)-2-substituted acetic acid derivatives, which bind to 
the LEDGF/p75 binding pocket at the IN dimer interface and block HIV replication44. Although compounds 
with different structures have been described, they all bind to the same pocket, and are therefore called LEDGINs. 
LEDGINs have a dual mechanism-of-action, inhibiting the LEDGF/p75-IN interaction and enhancing IN mul-
timerization45–48. More recently, LEDGINs were found to affect late stage HIV replication as well. The phenotype 
requires binding of LEDGINs to the LEDGF/p75 binding pocket on IN49,50 and is caused by enhanced multimer-
ization of IN in the virions resulting in morphological defects as evidenced by electron microscopy49,51–53.
While pools of HIV-1 particles are highly heterogeneous, studies of HIV nuclear entry are typically limited 
to population-averaged information. Here we performed single virus analysis to reveal the fate of single PICs, in 
particular their IN content and oligomeric state, during their journey into the nucleus. We employed HIV viral 
particles carrying fluorescent IN54 and two complementary microscopy approaches: 3D confocal microscopy 
and single-molecule Förster resonance energy transfer (FRET). Nuclear entry is associated with a reduction in 
the number of IN molecules in the PIC and upon nuclear entry the interaction with the host factor LEDGF/p75 
increases IN oligomerization. Addition of LEDGINs during virus production prematurely enhances IN oligomer-
ization in the virion, resulting in stable multimeric complexes in the cytoplasm that are defective for nuclear 
entry. This argues for a stringent size selection of the HIV IN complex for nuclear entry to occur.
Results
Single-virus analysis probes IN content and state. To investigate the fate of HIV IN during nuclear 
entry we generated single (or dual-) color fluorescently labeled lentiviral vectors by transfecting 293T producer 
cells with three (or four) plasmids, one (or two) of which encoding Vpr-IN-FP. IN is fused to a fluorescent protein 
(FP) and is actively targeted to assembling viral particles by viral protein R (Vpr), which is confirmed by Western 
blotting (Fig. 1A; Top and Supplementary Fig. S1). In contrast to the viral particles used in previous studies49,53,54, 
we now retained the wild-type (WT) IN sequence (and not the catalysis defective D64E mutant53,55) in the pack-
aging construct, resulting in viral particles that maintain 100% of the WT single-round infectivity (Fig. 1B). 
Confocal laser scanning microscopy (CLSM) was used to quantify the amount of IN-eGFP molecules present in 
a single viral complex (Fig. 1A; Middle). An advanced image analysis tool was developed, allowing automated 
detection of each fluorescent viral complex (HIVIN-eGFP), determination of their nuclear or cytoplasmic location 
and calculation of their fluorescence intensity (Supplementary Fig. S2). The intensity of each IN-eGFP viral com-
plex was calculated by fitting the point spread function (PSF) of each spot with a 2D Gaussian function, providing 
information about the number of labeled IN molecules per complex. Image acquisition and intensity calculations 
were carefully optimized and validated (Supplementary Fig. S3 and Supplementary Table S1). Quasi-total internal 
reflection fluorescence microscopy (quasi-TIRFM) was used for single-particle Förster resonance energy trans-
fer (FRET)-analysis to quantify the oligomeric state of IN inside viral complexes (HIVIN-mTFP1+IN-mVenus; Fig. 1A; 
Bottom). First, the FRET donor (“D, pre”; mTFP1) and acceptor (“A, pre”; mVenus) are imaged at low laser power. 
Subsequently, mVenus is photobleached at high laser power (“A, post”) followed by second imaging of the donor 
at low laser power (“D, post”). Based on the obtained fluorescence intensity of the fluorescent virions localized in 
both donor images (“D, pre” and “D, post”) a per-viral complex FRET ratio (Eq. 1) is calculated. If FRET occurs, 
the mean FRET ratio will be larger than unity. Changes in FRET ratio reflect changes in the interaction between 
different labeled IN subunits, resulting from altered stoichiometry, oligomerization affinity and/or conformation.
Validation of the functionality of the modified viruses was done using specific HIV-1 replication inhibitors. 
First, we used the small molecule inhibitor PF7456, which binds viral CA and affects reverse transcription (RT), 
uncoating and nuclear import in a dose dependent manner6,7,56,57. In agreement with the reported decrease in 
2-LTR circle formation (Fig. 1C)6,56, a nearly complete block in nuclear import was observed upon treatment with 
10 μ M PF74 (Fig. 1D). Secondly, treatment with an integrase strand transfer inhibitor (INSTI), either raltegra-
vir (RAL) or elvitegravir (EVG)58,59 resulted in PIC accumulation in the nucleus (Fig. 1D). This correlates with 
the increase in 2-LTR circles induced by INSTIs (Fig. 1C)60 and corroborates the existence of a fully functional 
intasome in at least a subset of the complexes. In summary, single-particle analysis of the fluorescent HIV viruses 
provides a valuable tool for assessing the IN content and oligomeric/conformational state of viral complexes 
during infection.
IN content and oligomerization state change in viral complexes upon nuclear entry. To quantify 
the amount of labeled IN inside a single viral complex, we calculated the fluorescence intensity of viral complexes 
in the different cellular compartments using our automated image analysis tool (Fig. 2A,B and Supplementary 
Table S2). As the fluorescence intensity appeared to be log-normally distributed, we used the geometric mean as 
a measure of intensity (Supplementary Fig. S4). Figure 2B reveals that cytoplasmic complexes have a two-fold 
higher intensity (1.035 ± 0.015 a.u.) compared to their nuclear counterparts (0.465 ± 0.016 a.u.), revealing that 
the latter contain less IN-eGFP molecules. To monitor the interaction between labeled IN subunits within viral 
complexes in the cell, we next quantified the FRET ratio. The FRET ratio of nuclear complexes (1.44 ± 0.07) was 
significantly higher than that in the cytoplasm (1.26 ± 0.01) (Fig. 2C and Supplementary Table S3), the latter 
value being similar with previous reported values for IN oligomers in the viral particles (1.27 ± 0.0953). We next 
sought to confirm these findings in cells more closely related to the physiological targets of HIV-1. Therefore we 
used a specific HIV enveloped virus (HIVEnv) trans-complemented with the IN-FP fusion protein to infect a T 
cell line (C8166)61 (Fig. 2D and Supplementary Tables S2 and 3) as well as primary CD4+ T cells (Fig. 2E and 
Supplementary Tables S2 and 3). Analysis of these cells corroborated the reduced IN content of viral complexes 
in the nucleus and the accompanying increase in FRET ratio (Fig. 2D,E and Supplementary Fig. S5). Importantly, 
in separate experiments, we could exclude that the observed changes in fluorescence intensity and FRET ratio are 
due to different environmental conditions in the cytoplasm and nucleus (Supplementary Fig. S6). Furthermore, 
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Figure 1. Single virus analysis probes IN content and conformation in functional viruses. (A) Top: HeLaP4 
cells are infected with VSV-G pseudotyped IN-labeled virus, produced via Vpr-transincorporation of IN-FP, 
for 6 hours (scissors: HIV protease recognition site). Middle: A 3D confocal image of an HIVIN-eGFP (green 
dots) infected HeLaP4 cell is acquired. The point spread function (PSF) of each IN-eGFP complex is fitted with 
a 2D Gaussian function to determine the fluorescence intensity, hence the quantity of IN-eGFP per complex. 
Scale bars: 5 μ m. Bottom: Quasi-TIRFM imaging of HIVIN-mTFP1+IN-mVenus in infected cells enables acceptor 
photobleaching (AP)-FRET measurements. The intensity of the donor (mTFP1; D, pre), quenched by the 
proximal acceptor (mVenus; A,pre), is dequenched after photobleaching of the acceptor (mVenus; A, post) and 
hence its brightness increases (mTFP1; D, post). The fluorescence intensity of each viral complex in both donor 
images (D, pre and D, post) is used to quantify the mean FRET ratio, as a measure for the interaction between 
IN subunits. Scale bars: 5 μ m. The 2D Gaussian function shows an increased fluorescence intensity of the donor 
(D, post) after acceptor photobleaching compared to the intensity before photobleaching (D, pre). (B) Single 
round infectivity of HIV, HIVIN-eGFP and HIVIN-mTFP1+IN-mVenus on HeLaP4 as measured by Firefly luciferase 
(fLuc) activity. Viruses are produced as in (A), the Vpr-transincorporated IN-FP is shown and ‘− ’ represents the 
absence of transincorporation. The mean relative luminescence units (RLU) of two experiments performed in 
triplicate, normalized for protein content of cell lysates is shown, error bars represent standard deviation.  
(C) qPCR analysis for the kinetics of 2-LTR circle formation in HeLaP4 cells after infection with HIV in the 
presence of DMSO, PF74 (10 μ M), RAL (0.6 μ M) or EVG (0.2 μ M) at 8, 24 and 48 h post infection. Error bars 
represent standard deviation of triplicates. (D) Percentage nuclear IN-eGFP complexes of cells treated with 
DMSO, PF74 (10 μ M), RAL (0.6 μ M) or EVG (0.2 μ M) during infection with HIVIN-eGFP. Error bars represent 
standard error of mean (SEM); *p-value < 0.05, ***p-value < 0.001 obtained with a Mann-Whitney test.
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Figure 2. Decrease in fluorescence intensity and increase in FRET ratio in the nucleus of HeLaP4, 
C8166 T and primary CD4+ T cells. (A) Representative confocal image of a lamin immunostained (blue) 
HeLaP4 cell infected with VSV-G pseudotyped HIVIN-eGFP for 6 h. Red arrows point towards nuclear IN-eGFP 
complexes. (B) Fluorescence intensity of HIVIN-eGFP complexes in infected HeLaP4 cells in the cytoplasm (black 
circle) and in the nucleus (grey circle), obtained using the automated image analysis tool. Box-plot whiskers 
represent 5th and 95th percentile, the median value is represented by the line within the box, and the square box 
depicts the mean. (C) Mean FRET ratios of HIVIN-mTFP1+IN-mVenus complexes in infected HeLaP4 cells in the 
cytoplasm (white) and in the nucleus (grey). (D) The left panel shows a representative confocal image of lamin 
immunostained (blue) C8166 T cells infected with HIVEnvIN-eGFP, containing a wild-type HIV envelope, for 
24 h. Red arrows indicate nuclear IN-eGFP complexes. Fluorescence intensity (middle) and mean FRET ratios 
(right) of HIV complexes in C8166 T cells infected with HIVEnvIN-eGFP and HIVEnvIN-mTFP1+IN-mVenus, respectively. 
(E) The left panel shows a representative confocal image of DAPI stained (blue) CD4+ T cells infected with 
HIVEnvIN-eGFP, containing a wild-type HIV envelope, for 24 h. Red arrows indicate nuclear IN-eGFP complexes. 
Fluorescence intensity (middle) and mean FRET ratios (right) are shown for HIV complexes in primary CD4+ 
T cells infected with HIVEnvIN-eGFP and HIVEnvIN-mTFP1+IN-mVenus, respectively. Error bars represent standard error 
of mean (SEM); ***p-value < 0.001, **p-value < 0.01 obtained with an unpaired Two Sample t-test with unequal 
variance of the data. Scale bar represents 5 μ m.
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immunolabeled HA-tagged IN revealed a similar reduction in nuclear IN content compared to cytoplasmic PICs 
(Supplementary Fig. S7 and Supplementary Table S4), excluding the possibility that the reduced nuclear IN con-
tent is an artifact because of the bulky eGFP tag. Taken together, these results suggest that the viral complex 
undergoes considerable changes in its composition (and conformation) upon nuclear entry.
Cellular cofactors affect IN oligomerization dynamics in the nucleus. Several cellular cofactors 
are involved in the replication cycle of HIV-1. TRN-SR2, for example, is a known nuclear import factor of HIV-1 
that interacts with IN (Fig. 3A)11,12,20. Hence, we infected HeLaP4 TRN-SR2 knockdown cells (TRN-SR2KD) and 
a scrambled control cell line (TRN-SR2SCR) (Fig. 3B) with HIVIN-eGFP or HIVIN-mTFP1+IN-mVenus. As expected, pre-
viously observed defects in nuclear import were confirmed (Supplementary Table S2)20. In both the TRN-SR2KD 
and TRN-SR2SCR a loss of IN molecules in the nucleus was observed (Fig. 3C and Supplementary Table S2), 
coinciding with an increase in FRET ratio (Fig. 3D and Supplementary Table S3), similar to HeLaP4 WT cells. 
Thus, the change in the number of IN-eGFP molecules and the FRET ratio proved to be TRN-SR2 independent.
Next, we investigated the effect of LEGDGF/p75, a nuclear cofactor that stabilizes the tetrameric form of 
IN (Fig. 3A)32,62,63, by infecting HeLaP4 LEDGF/p75 knockdown cells (LEDGF/p75KD) with HIVIN-eGFP or 
HIVIN-mTFP1+IN-mVenus. As a control for clonal selection artifacts, the LEDGF/p75 knockdown was reversed by 
Cre specific excision of the LEDGF/p75 knockdown cassette, reconstituting wild-type LEDGF/p75 expres-
sion (LEDGF/p75Flox) (Fig. 3B,E). A similar decrease in intensity of the nuclear HIVIN-eGFP viral complexes was 
observed in both LEDGF/p75KD and LEDGF/p75Flox cells, implying that the presence of LEDGF/p75 does not 
modulate the number of IN-eGFP molecules in the nucleus (Fig. 3F and Supplementary Table S2). However, 
in the LEDGF/p75KD cells no increase in nuclear FRET could be observed, contrary to the LEDGF/p75Flox case, 
where the FRET ratio in the nucleus was similar to that of HeLaP4 WT cells, suggesting that LEDGF/p75 is 
required for the observed nuclear FRET phenotype (Fig. 3G and Supplementary Table S3).
To prove the specificity of the LEDGF/p75 requirement for this phenotype, we introduced the INW131A substi-
tution, which is known to reduce the affinity of IN for LEDGF/p75 (Fig. 3H)43. Compared to HIVIN-mTFP1+IN-mVenus, 
HIVIN-W131A-mTFP1+IN-W131A-mVenus was hampered in forming IN oligomers with increased FRET in the nucleus 
(Fig. 3I and Supplementary Table S3), which is in line with its effect on LEDGF/p75 binding. Complete dis-
ruption of the IN-LEDGF/p75 interaction is obtained by introducing the D366N substitution in LEDGF/p7564. 
Back-complementation cell lines expressing D366N (LEDGF/p75D366N) or WT LEDGF/p75 (LEDGF/p75BC) were 
generated and their expression was verified by western blot (Fig. 3B). Although LEDGF/p75 expression levels 
varied among individual cells (HeLaP4 WT, LEDGF/p75Flox, LEDGF/p75BC and LEDGF/p75D366N) ubiquitous 
colocalization with chromatin was observed (Fig. 3E). As expected, the increase in FRET was rescued to WT 
levels in LEDGF/p75BC cells (Fig. 3J and Supplementary Table S3). In contrast, in cells back-complemented with 
LEDGF/p75D366N, the nuclear FRET ratio was not restored but similar to that obtained with INW131A (Fig. 3I and 
Supplementary Table S3) and in the LEDGF/p75KD cells (Fig. 3J and Supplementary Table S3). In conclusion, 
LEDGF/p75 but not TRN-SR2 orchestrates the interaction (and/or conformation) of IN subunits, yet does not 
define the quantity of IN molecules, in nuclear viral PICs.
Nuclear IN reorganization in the PIC occurs in the absence of LEDGF/p75-mediated chroma-
tin tethering. Whereas the LEDGF/p75 C-terminal part (IBD) interacts with HIV-1 IN, the N-terminal 
part of LEDGF/p75, consisting of a PWWP (Pro-Trp-Trp-Pro) domain, a nuclear localization signal (NLS), two 
AT-hooks and a supercoiled DNA recognition element ensures binding to chromatin and DNA35,36,65. To investi-
gate which domains of LEDGF/p75 are involved in the nuclear FRET increase, we generated a series of LEDGF/p75 
mutant constructs, specifically deleting or altering domains involved in chromatin binding (Supplementary Fig. S8) 
and reintroduced these to complement LEDGF/p75KD cells. Expression of the LEDGF/p75 truncations was ver-
ified by western blot (Fig. 4A) and immunocytochemistry (Fig. 4B). As shown before, endogenous LEDGF/p75 
was clearly excluded from nucleoli and localized to condensed chromatin during mitosis. Deletion of the PWWP 
domain (LEDGF/p7593–530) resulted in a more diffuse nuclear distribution and a loss of interaction with con-
densed chromatin (Fig. 4B)66. Complementation with the AT-hook mutant LEDGF/p75AT- (R183D, K192D and 
R196D)67 resulted in a similar localization as LEDGF/p75BC (Fig. 4B). In LEDGF/p7593–530 and LEDGF/p75AT- 
cells infected with HIVIN-mTFP1+IN-mVenus an increased FRET signal was observed for the nuclear complexes similar 
to LEDGF/p75BC cells (Fig. 4C and Supplementary Table S3), showing that chromatin tethering is not absolutely 
required to increase the FRET ratio in the nucleus.
Finally, we generated a construct encoding the C-terminal moiety of LEDGF/p75 (residues 325–530, including 
the IBD) fused to the C-terminus of a non-fluorescent eGFPY66L to increase protein stability (LEDGF/p75325–530)68. 
As a negative control we introduced the D366N mutation in the IBD to interfere with the interaction with HIV-1 
IN (LEDGF/p75325–530;D366N). Both constructs were transiently expressed in LEDGF/p75KD cells and these cells 
were subsequently infected with HIVIN-mTFP1+IN-mVenus particles. Noteworthy, an increased FRET signal in the 
nucleus of the LEDGF/p75325–530 expressing cells was observed, which was absent in the IN interaction-deficient 
LEDGF/p75325–530 expressing cells (LEDGF/p75325–530;D366N) (Fig. 4D and Supplementary Table S3). In conclusion, 
binding of the C-terminal part of LEDGF/p75 to IN is sufficient to increase the FRET signal in the nucleus, con-
firming its role in the nuclear dynamics of IN oligomers within the HIV PIC.
The nuclear pore acts as a molecular filter for HIV-1 nuclear import. While previous experiments 
point to LEDGF/p75 as the main determinant of the increased nuclear FRET ratio, the difference in the number 
of IN molecules per complex between cytoplasm and nucleus was LEDGF/p75 independent. Analysis of the 
spread in fluorescence intensity of single viral complexes revealed that the number of IN-eGFP molecules per 
complex varies considerably in the cytoplasm (1.035 ± 0.972 a.u. (geometric mean ± SD)) (Fig. 2B). This broad 
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range in IN content possibly reflects a heterogeneous population consisting of functional and non-functional 
viral particles, with defects in maturation, uncoating or reverse transcription, potentially influenced by a wide 
array of host defense mechanisms69. In stark contrast, the spread in intensity was much less pronounced among 
nuclear complexes (0.465 ± 0.239 a.u. (geometric mean ± SD)) (Fig. 2B). In theory these nuclear IN complexes 
may include functional intasomes, inactive IN aggregates or post-integration IN complexes. Since the same low 
intensity nuclear IN complexes were observed after inhibition of integration with INSTIs (RAL or EVG) (Fig. 5A, 
Supplementary Fig. S9 and Supplementary Table S5), we conclude that integration is not required to reduce the 
number of IN in nuclear PICs. Alternatively, the nuclear complexes may contain less IN due to gradual intas-
ome degradation over time. This would imply the existence of complexes with varying intensities in the nucleus, 
starting with high intensity complexes early post infection and the accumulation of low intensity particles over 
time. To investigate this possibility we performed a time-course, after a synchronized infection by incubating 
Figure 3. Cellular cofactor affects IN oligomerization dynamics in the nucleus. (A) The cellular cofactor 
TRN-SR2 has been implemented in HIV-1 nuclear import, while LEDGF/p75 tethers the PIC to the chromatin. 
(B) Western blot showing the depletion of TRN-SR2 and LEDGF/p75 respectively in TRN-SR2KD and  
LEDGF/p75KD cells. Other lanes represent LEDGF/p75 expression in the stable cell lines used in panel E.  
(C,D) Fluorescence intensity (C) and mean FRET ratios (D) in the cytoplasm (white) or nucleus (grey) in  
TRN-SR2KD, TRN-SR2SCR and HeLaP4 WT cells infected with VSV-G pseudotyped HIVIN-eGFP and  
HIVIN-mTFP1+IN-mVenus, respectively. (E) Representative confocal images of DAPI-stained (blue) and LEDGF/p75 
immunostained (red) HeLaP4 cells. Row 1: HeLaP4 WT cells (WT), row 2: LEDGF/p75 depleted cells  
(LEDGF/p75KD), row 3: reversal of LEDGF/p75KD by Cre specific excision of the LEDGF/p75 knockdown cassette 
reconstituting wild-type LEDGF/p75 (LEDGF/p75Flox), row 4 and 5: LEDGF/p75-depleted cells complemented 
with wild-type (LEDGF/p75BC) or mutant LEDGF/p75D366N. (F,G) Fluorescence intensity (F) and mean FRET 
ratios (G) in the cytoplasm (white) or nucleus (grey) in LEDGF/p75KD, LEDGF/p75Flox and HeLaP4 WT cells 
infected with VSV-G pseudotyped HIVIN-eGFP and HIVIN-mTFP1+IN-mVenus, respectively. (H) Crystal structure of the 
IN catalytic core dimer interface and the IBD of LEDGF/p75 (PDB 2B4J). The interface mutations W131A and 
D366N are indicated. (I) Mean FRET ratios in the cytoplasm (white) or nucleus (grey) in HeLaP4 cells infected 
with VSV-G pseudotyped HIVIN-W131A-mTFP1+IN-W131A-mVenus compared to HIVIN-mTFP1+IN-mVenus. (J) Mean FRET 
ratios in the cytoplasm (white) or nucleus (grey) in LEDGF/p75D366N, LEDGF/p75BC and LEDGF/p75WT cells 
infected with HIVIN-mTFP1+IN-mVenus. SCR = scrambled; KD = knockdown; BC = back-complemented. Unless 
explicitly stated otherwise, the intensity and mean FRET ratios in the cytoplasm and nucleus were statistically 
different (p-value < 0.001). (***p-value < 0.001, **p-value < 0.01 and n.s. = not significant).
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HIVIN-eGFP for two hours at 16 °C followed by a temperature shift to 37 °C which enables viral fusion70. HIVIN-eGFP 
complexes reached the cytoplasm already after two hours of incubation at 16 °C (zero hour time point) indicating 
endocytosis of VSV-G-pseudotyped virus or virus-like particles at 16 °C, resulting in incomplete synchronization. 
Nevertheless, at all time points tested from 2 to 24 h post infection, nuclear IN complexes displayed the same 
reduced intensity and spread (Fig. 5B and Supplementary Table S6). Together, these observations suggest that all 
HIV complexes that enter the nucleus already have a reduced intensity. We conclude from this analysis that the 
nuclear pore may act as a molecular filter, granting passage into the nucleus only to those complexes which have 
a reduced number of IN molecules.
To corroborate this hypothesis we produced viral particles in the presence of LEDGINs, which are known to 
enhance IN multimerization in newly formed particles (Fig. 5C). Indeed, production of HIVIN-mTFP1+IN-mVenus in the 
presence of LEDGINs resulted in a significantly higher FRET ratio (1.43 ± 0.03) (Fig. 5E)49,53. Remarkably, also the 
intensity of cytoplasmic IN complexes of pretreated virus was higher than in the untreated controls (Fig. 5D and 
Supplementary Table S7), evidencing the higher IN content of these complexes. Since DMSO and LEDGIN-treated 
HIVIN-eGFP particles had the same initial fluorescence intensity, equal amounts of IN-eGFP were present in the 
virus, and Vpr-transincorporation was unaffected (Fig. 5D and Supplementary Table S7). When infecting HeLaP4 
WT cells with LEDGIN-treated HIVIN-mTFP1+IN-mVenus viral particles, an invariable FRET ratio was observed for the 
HIV complexes in the cytoplasm (1.39 ± 0.03) and the nucleus (1.44 ± 0.09) (Fig. 5E and Supplementary Table S7) 
indicating that the enhanced multimerization state of IN inside the viral particle is retained throughout the early 
replication steps. Together with the intensity data, we therefore propose that LEDGIN-induced IN multimerization 
Figure 4. Nuclear IN reorganization in the PIC occurs in the absence of LEDGF/p75-mediated 
chromatin tethering. (A) Western blot showing LEDGF/p75 depletion in LEDGF/p75KD cell lines and the 
complementation with the respective LEDGF/p75 truncations. (B) Representative confocal images of  
LEDGF/p75-depleted cells complemented with wild-type (LEDGF/p75BC) or mutant LEDGF/p7593–530 or 
LEDGF/p75AT- during interphase and mitosis, stained for DAPI (blue) and immunostained for LEDGF/p75 
(red). LEDGF/p75BC but not LEDGF/p7593–530 binds mitotic chromatin. (C) Mean FRET ratios of VSV-G 
pseudotyped viral complexes (HIVIN-mTFP1+IN-mVenus) in the stable cell lines expressing the LEDGF/p75 
constructs (LEDGF/p7593–530, LEDGF/p75AT- and LEDGF/p75BC) compared to LEDGF/p75KD cells. (D) Mean 
FRET ratios of VSV-G pseudotyped viral complexes (HIVIN-mTFP1+IN-mVenus) in LEDGF/p75325–530 and  
LEDGF/p75325–530;D366N transfected LEDGF/p75KD cells. White bars: cytoplasm; grey bars: nucleus; 
KD = knockdown; BC = back-complemented. Unless explicitly stated otherwise, the intensity and FRET ratios 
in the cytoplasm and nucleus were statistically different (p-value < 0.001). (***p-value < 0.001, *p-value < 0.05 
and n.s. = not significant).
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during virus assembly results in an overly stable association of IN molecules. Hence, the nuclear import defect 
reported for LEDGIN pre-treated virus (Fig. 5F)49 may be directly related to the presence of this larger, static IN 
complex (LEDGIN-induced multimerization), which could be excluded from the nucleus. Taken together, these 
results suggest that the nuclear pore acts as a selective molecular filter for HIV nuclear import.
LEDGINs modulate nuclear but not cytoplasmic IN oligomers. Since LEDGINs are known to 
inhibit integration, we also investigated their effect on early stage replication. Upon addition of LEDGINs during 
infection (Fig. 6A) the fluorescence intensity of cytoplasmic HIVIN-eGFP complexes remained equal to that in the 
DMSO treated controls. Likewise the decrease in intensity upon entry in the nucleus was unaffected (Fig. 6B and 
Supplementary Table S8). Thus, LEDGINs do not affect the number of IN-eGFP molecules in the cytoplasm nor 
the loss of IN-eGFP upon nuclear entry. Nuclear import was not affected by LEDGINs when added during infec-
tion (Fig. 6C and Supplementary Table S5).
Since we have shown in this study that LEDGF/p75 increases the nuclear FRET ratio, we performed FRET 
experiments in LEDGF/p75KD cells in order to discriminate between possibly overlapping effects of LEDGINs 
and of LEDGF/p75. Interestingly, LEDGIN treatment during infection increased the FRET ratio in the nucleus, 
while that of the cytoplasmic HIVIN-mTFP1+IN-mVenus complexes was similar to that in the DMSO treated controls 
(Fig. 6D and Supplementary Table S8). Hence, only after entering the nucleus LEDGINs were able to modulate the 
IN conformation. In conclusion, LEDGINs modulate the IN oligomer but only after nuclear entry, pinpointing a 
second IN multimerization state-sensitive phase in the HIV replication cycle aside from viral particle assembly.
Discussion
To date, molecular details of nuclear entry of the HIV PIC remain obscure, therefore necessitating an experimen-
tal approach that allows single-virus analysis to address viral heterogeneity and avoid population averaging. Here 
we provide evidence for an HIV-1 nuclear entry/integration pathway orchestrated by the number and oligomeric 
state of integrase in the PIC. Since HIV-1 IN plays a major role throughout early replication, we probed HIV 
particles containing fluorescently labeled IN using sensitive single-virus microscopy techniques. By determining 
the fluorescence intensity of single viral particles (Fig. 1A; Middle), which is directly proportional to the number 
of labeled IN molecules, we assessed alterations in IN content during nuclear entry of the PIC (Figs 2 and 5). 
Figure 5. The nuclear pore acts as a molecular filter, impeding the nuclear import of LEDGIN pre-treated 
viral particles. (A) Fluorescence intensity of VSV-G pseudotyped HIV complexes (HIVIN-eGFP) in the cytoplasm 
(white) or nucleus (grey) of cells treated with DMSO, RAL (0.6 μ M) or EVG (0.2 μ M) during infection.  
(B) Fluorescence intensity of single IN-eGFP complexes in the cytoplasm (white circles) and nucleus (grey 
circles) at different time points post infection (0–24h). (C) Nuclear import of particles produced in the presence 
of DMSO or LEDGINs (1.2 μ M, CX14442) is hampered. (D) Fluorescence intensity of viral particles and viral 
complexes localized in the cytoplasm or nucleus of HeLaP4 WT cells infected with VSV-G pseudotyped  
HIVIN-eGFP particles produced in the presence of DMSO (white) or LEDGINs (1.2 μ M, CX14442) (grey).  
(E) FRET ratios of viral particles and viral complexes localized in the cytoplasm or nucleus in HeLaP4 WT cells 
infected with VSV-G pseudotyped HIVIN-mTFP1+IN-mVenus particles produced in the presence of DMSO (white) or 
LEDGINs (1.2 μ M, CX14442) (grey). (F) Percentage nuclear complexes (HIVIN-eGFP) in HeLaP4 cells infected 
with VSV-G pseudotyped particles produced in the presence of DMSO or LEDGINs (1.2 μ M, CX14442). 
Unless explicitly stated otherwise, the intensity and FRET ratios in the cytoplasm and nucleus were statistically 
different (p-value < 0.001). (***p-value < 0.001 and n.s. = not significant).
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Additionally, we measured FRET via acceptor photobleaching (Fig. 1A; Bottom)53 to quantitatively study the 
interaction between different IN subunits as well as the role of cellular cofactors in modulating IN oligomeriza-
tion upon nuclear entry (Figs 2, 3 and 4). Finally, we provide a mechanism to explain why viral particles assem-
bled in the presence of LEDGINs fail to enter the nucleus (Figs 5 and 6).
Single virus microscopy, a novel approach to study nuclear import and inhibitors. By using an 
HIV packaging construct that encodes WT IN instead of the catalytically defective IND64E  mutant20,53–55, fluo-
rescently labeled viral particles were generated with WT infectivity (Fig. 1B). Addition of the INSTIs, RAL or 
EVG, increased the number of nuclear IN-FP complexes (Fig. 1D). Since INSTIs only recognize IN assembled on 
processed vDNA into a specific intasome complex29,71, at least a subset of the detected nuclear IN-FP complexes 
must contain a functional intasome. In contrast, upon treatment with the CA-binding inhibitor PF74, hardly any 
IN-eGFP complexes were detected in the nucleus, which is in agreement with the reported drop in 2-LTR circle 
formation (Fig. 1C,D)6,7,56,57. Hence, single virus microscopy can be applied to study inhibitors of early steps of 
the HIV-1 replication cycle.
Detection of HIV complexes and quantification of their total fluorescence intensity using our automated anal-
ysis routine (Supplementary Fig. S2) offers an alternative for methods which count a limited number of HIV 
complexes by manually selecting a region of interest (ROI) and sum or average pixel intensities6,55,70. In our 
routine ROIs are automatically determined using an intensity threshold, which results in a higher precision and 
the unbiased processing of thousands of complexes within a few hours. Furthermore, the fluorescence intensity is 
quantified by fitting the PSF of each detected complex with a 2D Gaussian function, which automatically gener-
ates and subtracts an offset corresponding to the local background and is less affected by noise from the detector 
and excitation light fluctuations.
Upon nuclear entry, HIV IN complexes are modulated. Nuclear entry in HeLaP4 cells, a T cell line 
and primary T cells was associated with a modulation in both the composition of the IN multimer and its inter-
actions (Fig. 2). The chromatin tethering factor LEDGF/p75 but not the nuclear import factor TRN-SR2 proved 
to be the host factor responsible for increasing the IN FRET signal in the nucleus of HeLaP4 cells (Fig. 3). While a 
direct and Ran-dependent interaction between IN and TRN-SR2 was verified in vitro20,72, no correlation between 
formation of IN tetramers and TRN-SR2 binding has been observed73. The FRET data agree with the hypothesis 
that TRN-SR2 has no direct influence on IN oligomerization73. In contrast, LEDGF/p75 has originally been iden-
tified in a cellular complex with multimeric IN32 and the protein is known to modulate the dynamic structure of 
HIV-1 IN by stabilizing subunit-subunit interactions63. Although we cannot formally exclude an indirect effect of 
LEDGF/p75, inhibition of the interaction by a single interface substitution in IN-FP (INW131A)43 or LEDGF/p75 
(LEDGF/p75D366N) prevented the formation of a higher FRET oligomer (Fig. 3I,J). The modulation of the IN com-
plex architecture by LEDGF/p75 occurs upon nuclear entry, is mediated through the C-terminus of LEDGF/p75 
and is at least in part independent of chromatin tethering (Fig. 4C,D). Interestingly, whereas overexpression of 
the C-terminus of LEDGF/p75 in the nucleus of LEDGF/p75-depleted cells rescued the increase in FRET signal, 
cytoplasmic expression could not (Fig. 4D). Although De Rijck et al. showed that both transiently overexpressed 
mRFP-IN and eGFP-LEDGF/p75325–530 can interact in the cytoplasm68, our experiments indicate that IN in the 
context of a PIC is inaccessible for LEDGF/p75 prior to nuclear entry. This analysis is in line with mounting evi-
dence for a capsid cone that shields HIV proteins and DNA from the cellular environment during trafficking to 
the nuclear membrane7. The fact that LEDGF/p75 only engages IN upon nuclear entry might suggest that capsid 
uncoating only takes place at the nuclear pore as suggested by Arhel et al.3,74. Whether the observed reduction in 
IN upon nuclear entry is also required for LEDGF/p75 interaction still needs to be investigated.
Figure 6. LEDGINs alter the IN oligomer in the nucleus. (A) LEDGINs inhibit the interaction between 
LEDGF/p75 and IN by binding to the IN oligomer. (B) Fluorescence intensity of VSV-G pseudotyped  
HIVIN-eGFP complexes in the cytoplasm (white) or nucleus (grey) of HeLaP4 WT cells treated with DMSO or 
LEDGINs (45 μ M, CX14442) during infection. (C) Percentage nuclear IN-eGFP complexes in HeLaP4 WT 
cells treated with DMSO or LEDGINs (45 μ M, CX14442) during infection. (D) Mean FRET ratios of VSV-G 
pseudotyped HIVIN-mTFP1+IN-mVenus complexes in the cytoplasm (white) or nucleus (grey) of LEDGF/p75KD cells 
treated with DMSO or LEDGINs (45 μ M, CX14442) during infection. Unless explicitly stated otherwise, the 
intensity and FRET ratios in the cytoplasm and nucleus were statistically different (p-value < 0.001).  
(**p-value < 0.01 and n.s. = not significant).
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Apart from LEDGF/p75-induced IN multimerization, a second important alteration in the IN multimers 
was observed. Nuclear HIV PICs contain two-fold less IN-eGFP molecules than their cytoplasmic counterparts 
(Fig. 2B) and the nuclear population is considerably more homogeneous than the cytoplasmic with regard to IN 
content (Figs 2B and 5B). Using superresolution microscopy Lelek et al. showed that cytoplasmic PICs are gener-
ally larger in size than nuclear PICs75. Here we propose that IN content determines nuclear import. Since the NPC 
only allows access of macromolecules up to ~39 nm76, and since we also observed this IN ‘shedding’ in a T cell line 
and in primary CD4+ T cells infected with HIV-1 enveloped virus (Fig. 2D,E), we propose that the function as a 
size filter of the IN complex is a general feature for productive HIV nuclear import.
DNA viruses and retroviruses evolved different strategies to overcome this filter5,77. All seem to use Nup358 as 
docking platform. Whereas hepatitis B virus (~27 nm)78 enters the nuclear pore to uncoat and releases viral DNA 
upon arrival in the nuclear basket, the much larger herpes simplex virus (100 nm)79 uncoats on the cytoplasmic 
side of the nuclear pore. The HIV capsid cone is 100–150 nm long and 40–60 nm wide80, which is in between that 
of hepatitis B virus and the herpes simplex virus, requiring at least partial uncoating of the PIC for nuclear access8,9.
The mechanism of action of LEDGINs provides evidence for the nuclear pore filter. LEDGINs, 
small molecules recognizing the LEDGF/p75 binding pocket on HIV-1 IN, interfere with various steps of HIV-1 
replication37,44. By abrogating the IN-LEDGF/p75 interaction and promoting unproductive higher order IN oli-
gomerization they inhibit integration. Several groups confirmed that LEDGINs enhance IN multimerization 
within newly formed viral particles leading to maturation defects49,51–53. Here we show that the higher IN FRET 
signal obtained after LEDGIN treatment during virus production is retained during infection (Fig. 5E), arguing 
for very stable IN oligomeric states and a seemingly irreversible process. More importantly, LEDGIN-enhanced 
IN multimerization during assembly prevents the loss of IN molecules that is required for nuclear import in 
HeLaP4 cells because of the size limitation as shown here (Fig. 5D,E). Remarkably, the FRET ratio in the cyto-
plasm of cells infected with LEDGIN-treated viral particles is comparable with the LEDGF/p75-induced value 
observed in the nucleus with untreated virus (1.44 ± 0.07) (Fig. 5E). Although we cannot conclude that the under-
lying mechanism is exactly the same, LEDGINs may mimic the IN alteration obtained by interaction with nuclear 
LEDGF/p75 prematurely in the viral particles. Importantly, addition of LEDGINs during infection only increased 
the FRET signal in the nucleus but not in the cytoplasm (Fig. 6D). Since inaccessibility of the PIC to a small mole-
cule is unlikely, the IN oligomeric and/or conformational state in the cytoplasm seems to preclude modulation by 
LEDGINs. We cannot exclude that the observed IN ‘shedding’ upon nuclear entry is required for LEDGIN inter-
action. Alternatively, minute amounts of LEDGF/p75 or its C-terminus in the PIC81 may compete with LEDGIN 
binding in the cytoplasm. Although LEDGINs increase the FRET signal of IN to the same extent as LEDGF/p75, 
these ratios may correspond to entirely different complexes as suggested before82. In any case, the experiments 
with LEDGINs and LEDGF/p75 consistently indicate extensive changes in the IN multimer conformation and/
or composition upon nuclear entry.
Based on our results we propose the molecular mechanism of LEDGINs shown in Fig. 7. Upon nuclear entry 
through the NPC the IN complex is modulated. First, a large part of the viral proteins, including labeled IN 
molecules, which are not tightly associated with the vDNA or other PIC components, are lost. Our data do not 
contradict the growing evidence that capsid uncoating takes place at the nuclear membrane74. Still, from our data 
we cannot conclude whether complexes which already have a reduced number of IN-eGFP molecules are the only 
ones that can enter or whether active IN uncoating takes place at the NPC. Subsequently, the vDNA associated 
with at least four IN molecules (but probably more) is imported in the nucleus.
Second, upon arrival in the nucleus, the IN complex is modulated by LEDGF/p75. We consider a scenario 
according to which IN first assembles on the vDNA ends29, after which the IN tetramer-vDNA ends complex 
engages LEDGF/p7583. Finally, this nucleoprotein complex is tethered by LEDGF/p75 to active transcription 
units and primed for successful integration. By enhancing IN multimerization prematurely, LEDGINs interfere 
with virus assembly, reverse transcription, IN uncoating and thus nuclear import, IN oligomerization dynam-
ics upon nuclear entry and chromatin tethering. This multifaceted mechanism of action explains their antiviral 
potency. Collectively, using the power of single-virus analysis to study the fate of HIV IN during viral replication 
we show for the first time the requirement for a PIC IN ‘uncoating step’ during nuclear entry as well as a role of 
LEDGF/p75 in directing the oligomerization or conformational dynamics of IN in the nuclear PIC.
Materials and Methods
Virus production for fluorescence intensity and FRET measurements. Vesicular stomatitis virus 
glycoprotein (VSV-G)-pseudotyped HIV-1-derived viral particles containing fluorescently labeled IN (HIVIN-eGFP 
and HIVIN-mTFP1+IN-mVenus) were generated by Vpr-mediated trans-incorporation53,54. 6.5 × 106 HEK293T producer 
cells were seeded per 10 cm petri dish in DMEM supplemented with 2% FBS. At a density of 90%, cells were 
transfected using branched polyethylenimine (bPEI, 10 μ M, Sigma-Aldrich) with 5 μ g pVSV-G, 15 μ g pNL4–3.
Luc.R−.E− and a specific amount of Vpr-IN-FP-encoding plasmid. HIVIN-eGFP was produced with 15 μ g of Vpr-IN-
eGFP plasmid, while HIVIN-mTFP1+IN-mVenus was produced with 2 μ g of each Vpr plasmid per dish (Vpr-IN-mTFP1 
and Vpr-IN-mVenus). Six hours post-transfection, the medium was replaced with pre-warmed OptiMEM (Life 
Technologies) supplemented with 50 μ g/mL gentamicin (Invivogen). Supernatant was collected 48 h post-trans-
fection, filtered through a 0.45 μ m filter (Sartorius), and concentrated by ultracentrifugation on a 60% (w/v) 
iodixanol cushion on room temperature (131,500 g, 90 min, SW28 rotor, Beckman Coulter, Ireland). Next, the 
iodixanol was removed by ultrafiltration (Vivaspin, MWCO 50K, Merck, Overijse, Belgium). For the production 
of viruses in the presence of LEDGINs or DMSO, the transfection medium was replaced with fresh OptiMEM 
supplemented with CX14442 (1.2 μ M, 20 × IC50, synthesized by the KU Leuven Centre for Drug Design and 
Development (CD3)) or an equal volume of DMSO. HIV-enveloped viral particles containing fluorescently labe-
led IN (HIVEnvIN-eGFP and HIVEnvIN-mTFP1+IN-mVenus) were produced in a similar way, with the following changes: 
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cells were transfected with 20 μ g pNL4-3 and 15 μ g of Vpr-IN-eGFP plasmid, or 2 μ g Vpr-IN-mTFP1 and Vpr-
IN-mVenus plasmid, supernatant was collected 48 and 72 h post transfection and the virus was concentrated by 
ultrafiltration (Vivaspin, MWCO 50K) without ultracentrifugation.
Infection of HeLaP4 cells. 3 × 104 HeLaP4 cells were seeded per well in poly-D-lysine (0.1 mg/ml, Sigma) 
coated 8-well chambered cover glasses (Nunc Lab-Tek Chambered Coverglasses, 155411, Thermo Scientific) and 
infected the next day with an amount (1–4 μ g of p24 antigen) of HIVIN-eGFP or HIVIN-mTFP1+IN-mVenus. Different viral 
preps (e.g. production with DMSO or LEDGINs) were normalised on p24 antigen content in order to infect with 
the same amount of virus. Six hours post-infection, cells were briefly incubated with trypsin (0.25% (w/v), 30 s, 
Life Technologies), washed with PBS and fixed with 4% (v/v) paraformaldehyde. See Supplementary methods 
for immunocytochemistry. When inhibitors PF-03450074 (PF74) (10 μ M, SML0835, Sigma), raltegravir (0.6 μ M, 
100 × IC50, NIH AIDS Reagent Program, Division of AIDS, NIH (Cat #11680) from Merck & Company, Inc), 
elvitegravir (0.2 μ M, 100 × IC50), CX14442 (30–45 μ M) or DMSO were used during infection, cells were first 
pre-incubated for 2 h with the respective compound, after which the virus was added in the presence of the inhibitor 
for 6 h. See Supplementary methods for infection of C8166 T cells and CD4+ T cells. For time course measurements 
infection was synchronised. Therefore, pre-cooled HeLaP4 cells (15 min at 4 °C) were infected for 2 h at 16 °C (zero 
time point) followed by a temperature shift to 37 °C to allow viral entry70. After 2 h of incubation at 37 °C (2 h time 
point), cells were washed with pre-warmed OptiMEM, and further incubated to reach a total infection time of 24 h.
Confocal microscopy and data analysis for nuclear import and intensity measurements. 
Imaging of cells and viral particles was performed using a laser scanning microscope (Fluoview FV1000, 
Olympus, Tokyo, Japan). See Supplementary methods for specifications of the microscope and image acquisition.
The automatic detection, localization and intensity calculation of each IN-eGFP complex was performed using 
a homemade MatLab routine (The MathWorks, Inc.) (See also Supplementary Fig. S2). In brief, after image pro-
cessing, particles were automatically detected using an intensity threshold. This threshold is calculated using the 
triangle algorithm84 with addition of the double of the mean image intensity of each z-slice. Each fluorescent 
spot that consisted of less than 7 pixels above the threshold was excluded. The remaining spots were assigned to 
be part of a single IN-eGFP complex if they were observed in at least 3 consecutive z-slices, with the complex at 
a maximum distance of 3 pixels (309 nm). Large aggregates were removed manually. Subsequently, the nuclear 
lamin was determined using intensity thresholding (triangle algorithm with addition of the mean image inten-
sity), and then used for automatic assignment of complexes to cytoplasm or nucleus. The percentage of nuclear 
complexes per cell was calculated and the mean over all cells represents the final percentage of nuclear IN-eGFP 
complexes. Since the fluorescence signal of each complex is diffraction limited, the point spread function of each 
Figure 7. Model for nuclear entry of IN labeled PIC. The early stages of the HIV replication cycle in an 
infected cell are shown. After infection of cells, WT IN (gray circle) and labeled IN (green circle) associated with 
reverse transcribed vDNA are imported into the nucleus assisted by TRN-SR2 as part of the pre-integration 
complex (PIC). Nuclear entry of the PIC requires loss of IN-eGFP and is inhibited when stable multimeric 
IN complexes are present. Stable multimeric complexes are formed when LEDGINs (blue circles) are present 
during the production of new virus. LEDGINs can bind to the polyprotein precursor containing IN or to the 
mature IN. When bound, LEDGINs enhance IN multimerization forming stable multimeric complexes and a 
block in nuclear import. Upon nuclear entry of functional complexes, LEDGF/p75 (red circle) binds to the IN 
complex, resulting in an oligomer with a higher FRET ratio, activated for efficient integration. When LEDGINs 
(blue circle) are present during PIC nuclear import, they compete with LEDGF/p75 for binding to IN. LEDGINs 
inhibit integration by preventing IN-LEDGF/p75 complex formation and enhancing IN oligomerization.
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spot was fitted with a 2D Gaussian using the least-mean-square method to calculate the integrated intensity of 
each IN-eGFP complex. The integrated intensity of this function was calculated in each z-slice. Since the z-slice in 
which the complex is in focus is expected to have the highest intensity, this intensity value was selected for further 
use. Complexes for which the fitted 2D Gaussian had widths (σ x and σ y) larger than 2 pixels were excluded since 
these are assumed to be aggregates. Typically, data were collected from at least 30 different cells, which correspond 
to at least 1000 detected complexes per experiment. Each experiment was performed at least twice and data from 
a representative experiment are shown. The mean percentage of nuclear complexes is presented in a bar diagram, 
with the standard error of mean (SEM) as error bars. P-values are obtained from a Mann-Whitney test. Intensity 
data are presented as individual data points overlaid with a box-plot, whiskers representing the 5th and 95th 
percentiles. The median value is represented by the line within the box and the square box depicts the mean. Bar 
diagrams represent the geometric mean of the intensity data, error bars are the back-transformed standard error 
of the mean (See also Supplementary Fig. S4). P-values for the intensity data are obtained from a Two-sample 
t-test with unequal variance of the log-normal distributed data with p-value < 0.001 (***), p < 0.01 (**), p < 0.05 
(*) and n.s. = not significant as the criterion of significance.
Quasi-TIRF microscopy and data analysis for FRET measurements. FRET measurements were 
performed on an inverted microscope (Olympus IX-83, Olympus NV). See Supplementary methods for speci-
fications of the microscope and image acquisition. Single viral complexes (HIVIN-mTFP1+IN-mVenus) were localized 
by dual-color 2D Gaussian localization of the sub diffraction viral complexes (100–150 nm). Subsequently, the 
single-particle integrated fluorescence intensity per virus of the FRET donor before (FD,pre) and after (FD,post) 
photobleaching and of the FRET acceptor was extracted. Single-molecule localization/fitting was performed with 








If FRET occurred between donor and acceptor, an increase of the donor fluorescence is observed after pho-
tobleaching of the acceptor. Typically, data were collected from ~50–100 different cells, corresponding to an aver-
age of ~200–2000 viral complexes per measurement. From all the obtained FRET ratios, the average was taken 
and the error bars on the bar graphs represent the standard error of the mean (SEM). Statistical analyses were 
performed with a Two-sample t-tests with unequal variance with the following p-value cutoffs: p < 0.001 (***), 
p < 0.01 (**), p < 0.05 (*) and n.s. = not significant.
Ethics statement. The human peripheral blood mononuclear cells were isolated from anonymous healthy 
blood donors. Buffy coats were obtained from the Red Cross Blood transfusion Center (Mechelen, Belgium) 
according to approved bioethical guidelines (S57175-IRB00002047) of the ethical committee of our institute, with 
informed consent of all donors. All methods were carried out in accordance with the guidelines and regulations of 
KU Leuven. All experimental protocols were approved by the HSE department of KU Leuven.
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